Researchers at the Korea Research Institute of Bioscience and Biotechnology have developed a pioneering nanobody-based therapy designed for precise targeting of lung cancer tumors. This innovative approach utilizes uniquely engineered nanobodies that offer high specificity and potent antitumor activity, potentially overcoming current therapeutic limitations. The technology opens new avenues for improving immunotherapy efficacy against aggressive lung malignancies with minimized off-target effects.